Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Profit After Tax: 2009-2024

Historic Profit After Tax for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to -$20.1 million.

  • OptimizeRx's Profit After Tax rose 10853.79% to $779000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $34000.0, marking a year-over-year increase of 10014.07%. This contributed to the annual value of -$20.1 million for FY2024, which is 1448.25% down from last year.
  • Latest data reveals that OptimizeRx reported Profit After Tax of -$20.1 million as of FY2024, which was down 1448.25% from -$17.6 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Profit After Tax registered a high of $378079.0 during FY2021, and its lowest value of -$20.1 million during FY2024.
  • For the 5-year period, OptimizeRx's Profit After Tax averaged around -$10.2 million, with its median value being -$11.4 million (2022).
  • Its Profit After Tax has fluctuated over the past 5 years, first soared by 11712.99% in 2021, then tumbled by 312541.0% in 2022.
  • Over the past 5 years, OptimizeRx's Profit After Tax (Annual) stood at -$2.2 million in 2020, then surged by 117.13% to $378079.0 in 2021, then plummeted by 3125.41% to -$11.4 million in 2022, then plummeted by 53.57% to -$17.6 million in 2023, then dropped by 14.48% to -$20.1 million in 2024.
  • Its Profit After Tax stands at -$20.1 million for FY2024, versus -$17.6 million for FY2023 and -$11.4 million for FY2022.